Showing results (451-460 of 491) with videos related to

Sort By:
Pageof 50
Diabetes Technology & Therapeutics|December 27, 2018
Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 DiabetesGregory P Forlenza, Orit Pinhas-Hamiel, David R Liljenquist, et al.
Diabetes, Obesity & Metabolism|January 9, 2026
Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-studyJean-Pierre Riveline, Eric Renard, Grazia Aleppo, et al.
Diabetes Care|June 26, 2018
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 StudyJohn B Buse, Satish K Garg, Julio Rosenstock, et al.
Diabetes Technology & Therapeutics|February 6, 2025
Safety and Effectiveness of MiniMedTM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 DiabetesAnuj Bhargava, Richard M Bergenstal, Mark L Warren, et al.
Oncogenesis|June 12, 2020
Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gammaPhilip Weidner, Michaela Söhn, Torsten Schroeder, et al.
Diabetes Care|October 18, 2024
Efficacy and Safety of a Tubeless AID System Compared With Pump Therapy With CGM in the Treatment of Type 1 Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel-Group Clinical TrialEric Renard, Ruth S Weinstock, Grazia Aleppo, et al.
Diabetes Technology & Therapeutics|August 1, 2018
Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 DiabetesRobert H Slover, Jeanie B Tryggestad, Linda A DiMeglio, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 25, 2024
Metagenomic study of lake microbial mats reveals protease-inhibiting antiviral peptides from a core microbiome memberChandrashekhar Padhi, Christopher M Field, Clarissa C Forneris, et al.
Nature Medicine|October 3, 2022
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trialJeremy Pettus, Schafer C Boeder, Mark P Christiansen, et al.
Diabetes Technology & Therapeutics|October 10, 2018
In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 DiabetesMichael A Wood, Dorothy I Shulman, Gregory P Forlenza, et al.
Pageof 50